Management Team

Write here…

JERRY WILLIAMSON
CEO

Jerry is a performance-driven, entrepreneur with over thirty years of progressive leadership experience in bioscience markets for research, diagnostic and analytical products.  Prior to joining NanoView Biosciences, Jerry was the CEO of KEW, Inc. and Metamark Genetics Inc., both cancer diagnostic companies, and President of Genetix LLC, Biacore Inc., and Pyrosequencing, Inc., analytical technology companies in life science.  Jerry has a successful track record of establishing and managing profitable businesses, recruiting and developing top-performing global commercial organizations, creating substantial shareholder value through business development, licensing, and strategic partnerships, raising capital, and completing successful exits.  He holds a BS in Biochemistry from the University of Vermont and an MBA in Entrepreneurship from Boston University.

Dr-DAVID-FREEDMAN_CEO_NanoView.png

DAVID FREEDMAN
President & COO

David is a co-founder and founding CEO of NanoView Biosciences. David has played a key role in NanoView’s entry into the extracellular vesicle market with the launch of the ExoView™ R100, and since 2018 has led worldwide operations for all NanoView's products. A problem-solver and entrepreneur for over a decade, David formerly served as CTO of eHomes, and as President of a computer services company. Performance history includes new product and services development, commercialization strategy and organizational buildout, and high-tech engineering and automation. David was educated at UCSD in Electronics and Economics before moving to Boston University to complete his PhD and PostDoc in Electrical Engineering.  

Dr-GEORGE-DAABOUL-President-CSO-Nanoview.png

GEORGE DAABOUL
CSO

George co-invented the Single Particle Interferometric Reflectance Imaging Sensor (IRIS) in Dr. Ünlü’s lab, which is the fundamental technology on which the ExoView platform is based on. George’s graduate work focused on the development of biosensors for digital detection and counting of viral pathogens and cancer biomarkers. George has published numerous papers on the sensitive, multiplexed detection of viral hemorrhagic fever viruses (Ebola and Marburg) from serum and whole blood. As a full-time CSO at NanoView Biosciences, George leads the assay development and validation of the ExoView cartridge.

 
ANDREW-MALLOY-VP-Sales-and-Marketing.png
MCreighton_edited.png

ANDREW MALLOY
VP of Sales & Marketing

Andrew has been involved with innovative technologies within the extracellular vesicle field for nearly 15 years. He is one of the original members of the NanoSight team responsible for developing and commercializing Nanoparticle Tracking Analysis (NTA) prior to the business selling to Malvern Instruments.  Prior to joining NanoView, Andrew was CEO of Oxford Nanoimaging.  Andrew has a successful track record in the commercialization of technology solutions associated with the extracellular vesicle field and beyond. Andrew holds a BS in Biomedical Engineering, a Master of Science in Biomedical Engineering and an MBA specializing in entrepreneurship from Liverpool University.

MICHAEL CREIGHTON
VP of Finance

Michael has over 10 years of financial management and public accounting experience, in varying stage global private and public companies mainly in the Biotechnology and Life Sciences Industries.  Prior roles include positions at KEW Inc., Repligen, and PricewaterhouseCoopers.  He is a Certified Public Accountant who holds a BA and MBA from Saint Bonaventure University.  Michael joined NanoView in January 2019 to lead the Finance and Administrative functions.

 

Board of Directors

PARKER-CASSIDY.png
IAN-RATCLIFFE-.png
PMajor_edited.png

PARKER CASSIDY

Parker has spent over a decade as an entrepreneurial general manager with leadership experience in diagnostics, medical devices, and research tools at Becton Dickinson and Millipore. Parker’s  expertise extends to profit and loss management, new product development, strategy development, mergers and acquisitions/integration, and new team formation. Parker was recently an Entrepreneur in Residence at RA Capital Management and is currently Chief Commercial Officer at Mitra Biotech, a cancer diagnostic company.

IAN RATCLIFFE

Ian was the Chairman and CEO of Enzymatics, and was a founder, CEO, and director of Stemgent Inc., a life science company. Prior to Stemgent, he served as President of Upstate, a leading provider of cell signaling research products and services. In this position, Ian was instrumental in facilitating the acquisition of Upstate by Serologicals, Corp., and was retained as President of the Upstate division.  Ian earned a degree in Chemical Engineering from University of Surrey and an MBA from the Darden Graduate School of Business Administration at the University of Virginia. He is a director of Global Cell Solutions LLC, a biotech company commercializing proprietary 3D cell culture technology.

PAXTON MAJOR

Paxton is a member of the investment team at Northpond Ventures, a formative stage venture-capital fund based in the Washington DC area. Paxton is an active Board Observer at SeLux, DiCE Molecules, Mitra Biotech, and Candel Therapeutics. Prior to joining Northpond, Paxton worked as a consultant for Trinity Partners, a global life sciences strategic consulting company in Boston, MA, where he focused on corporate strategy, licensing & acquisition, and pipeline & portfolio optimization. Paxton earned a B.S. in Neurobiology from Brown University.